- $1.35bn
- $1.00bn
- 44
- 25
- 48
- 33
Annual income statement for Disc Medicine, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | 10-K | 10-K | 10-K | 10-K |
Standards: | — | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | — | 0.813 | 69.7 | 47.5 | 91.1 |
Operating Profit | 0 | -0.813 | -69.7 | -47.5 | -91.1 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | — | -0.813 | -71.9 | -46.8 | -76.3 |
Provision for Income Taxes | |||||
Net Income After Taxes | — | -0.813 | -71.9 | -46.8 | -76.4 |
Net Income Before Extraordinary Items | |||||
Net Income | — | -0.813 | -71.9 | -46.8 | -76.4 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 0 | -0.813 | -71.9 | -46.8 | -76.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | — | -0.53 | -17.6 | -2.69 | -3.42 |